Cargando…
Regulatory Scientific Advice on Non-Inferiority Drug Trials
The active-controlled trial with a non-inferiority design has gained popularity in recent years. However, non-inferiority trials present some methodological challenges, especially in determining the non-inferiority margin. Regulatory guidelines provide some general statements on how a non-inferiorit...
Autores principales: | Wangge, Grace, Putzeist, Michelle, Knol, Mirjam J., Klungel, Olaf H., Gispen-De Wied, Christine C., de Boer, Antonius, Hoes, Arno W., Leufkens, Hubert G., Mantel-Teeuwisse, Aukje K. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3764030/ https://www.ncbi.nlm.nih.gov/pubmed/24040346 http://dx.doi.org/10.1371/journal.pone.0074818 |
Ejemplares similares
-
Regulatory scientific advice in drug development: does company size make a difference?
por: Putzeist, Michelle, et al.
Publicado: (2010) -
Drug development for exceptionally rare metabolic diseases: challenging but not impossible
por: Putzeist, Michelle, et al.
Publicado: (2013) -
Challenges of defining a non-inferiority margin: a case study of non-inferiority randomized controlled trials of oral anti-thrombolytic agents for prophylaxis of venous thromboembolic events after orthopedic surgery
por: Wangge, Grace, et al.
Publicado: (2011) -
Room for Improvement in Conducting and Reporting Non-Inferiority Randomized Controlled Trials on Drugs: A Systematic Review
por: Wangge, Grace, et al.
Publicado: (2010) -
Phase IV non-inferiority trials and additional claims of benefit
por: Bernabe, Rosemarie DLC, et al.
Publicado: (2013)